DHG Pharmaceutical JSC (HOSE:DHG)
Vietnam · Delayed Price · Currency is VND 100,400
+100 (0.10%)
At close: Apr 10, 2026
DHG Pharmaceutical JSC Cash Flow Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 852,354 | 778,920 | 1,050,663 | 988,455 | 777,220 |
Depreciation & Amortization | 118,029 | 169,695 | 88,704 | 81,001 | 82,564 |
Other Amortization | 978.85 | - | - | - | 1,299 |
Loss (Gain) From Sale of Assets | -120,583 | -139,127 | -203,609 | -112,319 | -106,218 |
Other Operating Activities | 17,665 | -9,538 | -11,828 | -56,715 | -43,544 |
Change in Accounts Receivable | -54,941 | 105,103 | -268,589 | 34,206 | 22,427 |
Change in Inventory | 86,655 | 420,960 | -286,890 | -177,950 | -246,313 |
Change in Accounts Payable | 289,927 | -21,510 | -129,051 | 160,321 | -33,242 |
Change in Other Net Operating Assets | 22,882 | 13,080 | 772.15 | -15,714 | -1,749 |
Operating Cash Flow | 1,212,968 | 1,317,583 | 240,171 | 901,285 | 452,444 |
Operating Cash Flow Growth | -7.94% | 448.60% | -73.35% | 99.20% | -45.24% |
Capital Expenditures | -31,136 | -88,705 | -486,343 | -233,992 | -24,562 |
Sale of Property, Plant & Equipment | 1,240 | 967.73 | 1,654 | 3,334 | 4,632 |
Investment in Securities | - | - | - | 3,206 | 84.72 |
Other Investing Activities | 120,628 | 156,786 | 179,869 | 118,723 | 101,430 |
Investing Cash Flow | 811,731 | -445,951 | -179,819 | -353,729 | 45,694 |
Short-Term Debt Issued | 1,321,447 | 1,708,085 | 1,524,390 | 737,941 | 794,683 |
Total Debt Issued | 1,321,447 | 1,708,085 | 1,524,390 | 737,941 | 794,683 |
Short-Term Debt Repaid | -1,971,361 | -1,630,335 | -1,066,949 | -830,609 | -799,564 |
Total Debt Repaid | -1,971,361 | -1,630,335 | -1,066,949 | -830,609 | -799,564 |
Net Debt Issued (Repaid) | -649,914 | 77,749 | 457,441 | -92,668 | -4,880 |
Common Dividends Paid | -1,307,461 | -980,596 | -457,611 | -457,611 | -522,984 |
Financing Cash Flow | -1,957,375 | -902,846 | -170.11 | -550,279 | -527,865 |
Foreign Exchange Rate Adjustments | -286.21 | -62.53 | -65.74 | -222.19 | 45.25 |
Net Cash Flow | 67,038 | -31,276 | 60,116 | -2,946 | -29,681 |
Free Cash Flow | 1,181,831 | 1,228,879 | -246,171 | 667,293 | 427,882 |
Free Cash Flow Growth | -3.83% | - | - | 55.95% | -41.97% |
Free Cash Flow Margin | 22.44% | 25.16% | -4.91% | 14.27% | 10.69% |
Free Cash Flow Per Share | 9039.13 | 9398.97 | -1882.82 | 5103.73 | 3272.62 |
Cash Interest Paid | 26,020 | 24,766 | 29,299 | 12,558 | 12,050 |
Cash Income Tax Paid | 124,797 | 101,297 | 104,854 | 100,999 | 99,613 |
Levered Free Cash Flow | 554,112 | 1,955,870 | -506,459 | 447,363 | 260,730 |
Unlevered Free Cash Flow | 570,134 | 1,971,377 | -488,003 | 455,212 | 268,280 |
Change in Working Capital | 344,523 | 517,633 | -683,758 | 862.86 | -258,877 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.